Role of Human Apolipoprotein E in Hepatitis B Virus Infection and Morphogenesis
Role of Human Apolipoprotein E in Hepatitis B Virus Infection and Morphogenesis
批准号:
10267767
负责人:
GUANGXIANG George LUO
金额:
$42.04万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-22 至 2025-08-31
关键词:
AffectAntibodiesAntiviral AgentsAntiviral TherapyApolipoprotein EBindingBiological AssayBiologyCell Culture SystemCell Culture TechniquesCell LineCessation of lifeChronicChronic HepatitisChronic Hepatitis BCircular DNACirrhosisClinicalCo-ImmunoprecipitationsCysteineDNA VirusesDataDevelopmentElectron MicroscopyFamilyFamily memberFibrosisGenesGenomeGlucosamineGlypicanGoalsHepadnaviridaeHeparan Sulfate ProteoglycanHeparinHepatitis BHepatitis B VaccinesHepatitis B VirusHepatocyteHumanImmunologicsIndividualInfectionInfectious hepatitidesInterferonsKnock-outKnowledgeLDL-Receptor Related Protein 1Liver diseasesLow Density Lipoprotein ReceptorMediatingMediationMolecularMolecular TargetMonoclonal AntibodiesMorphogenesisMusMutagenesisOutcomePatientsPhosphorylationPhysiologicalPlayPrimary carcinoma of the liver cellsProductionProteinsPublic HealthRiskRoleSmall Interfering RNASurfaceTestingTherapeuticUnited StatesVaccinesViral hepatitisVirionVirusVirus DiseasesVirus ReplicationWorld Health Organizationbasechronic liver diseasedrug developmentdrug discoveryenv Gene Productsglobal healthglycosylationin vivoinhibitor/antagonistknock-downnovelnucleoside analogpreventproteoglycan core proteinprototypereceptorreceptor bindingvirus envelopevirus host interaction
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Summary
Hepatitis B virus (HBV) is a common cause of human liver diseases, including chronic hepatitis, steatosis,
fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). HBV chronically infects more than 250 million people
worldwide, including 1.25 million in the United States. Although HBV vaccine has greatly contributed to the
reduction of new cases of HBV infection and HCC, it does not offer therapeutic benefits to the hundreds of
millions of chronic HBV carriers. The World Health Organization has called for the elimination of viral hepatitis as
a public health threat by the year 2030. The biggest challenge to curing chronic hepatitis B is the elimination of
HBV covalently closed circular DNA (cccDNA), which is the molecular basis for persistent HBV replication.
Existing antiviral therapies with interferon and/or nucleoside analogs can effectively suppress HBV replication
but do not significantly affect the level of HBV cccDNA. Thus, there is an urgent need to discover and develop
new classes of antiviral drugs capable of eliminating chronic HBV infection. In this regard, a more thorough
understanding of HBV infection, replication, and morphogenesis holds a great promise to identify novel targets
for antiviral drug discovery and development. Through preliminary studies, we have discovered that human
apolipoprotein E (apoE) is associated with infectious HBV. More importantly, our preliminary data suggest that
apoE plays critical roles in both HBV infection and morphogenesis. ApoE-specific antibodies could efficiently
neutralize HBV infectivity. Also, knockdown of apoE expression or knockout of apoE gene resulted in a
remarkable reduction of HBV infection and production. Based on these novel findings, we hypothesize that
apoE is incorporated into HBV virions and plays important roles in HBV infection and morphogenesis in vivo. The
overall goal of this application is to determine the role and underlying molecular mechanisms of apoE in the
promotion of HBV infection and morphogenesis in cell culture and in vivo. Our specific aims are: 1) to determine
the importance of apoE in the infection and morphogenesis of clinical HBV isolates; 2) to determine apoE-binding
receptors and apoE-receptor interactions important for efficient HBV infection; and 3) to illustrate the underlying
molecular mechanism of apoE-mediated promotion of HBV morphogenesis. The successful completion of this
application will result in a paradigm change regarding the roles of cellular proteins in HBV infection and
morphogenesis. The outcomes of our studies will also provide novel molecular targets for discovery and
development of antiviral drugs towards the ultimate elimination of HBV infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cell surface receptors promoting hepatitis B virus infection
-
批准号:10617179
-
项目类别:
-
资助金额:$46.88万
-
财政年份:2020
-
负责人:GUANGXIANG George LUO
-
依托单位:
Role of Human Apolipoprotein E in Hepatitis B Virus Infection and Morphogenesis
-
批准号:10462638
-
项目类别:
-
资助金额:$42.04万
-
财政年份:2020
-
负责人:GUANGXIANG George LUO
-
依托单位:
Role of Human Apolipoprotein E in Hepatitis B Virus Infection and Morphogenesis
-
批准号:10119861
-
项目类别:
-
资助金额:$42.04万
-
财政年份:2020
-
负责人:GUANGXIANG George LUO
-
依托单位:
Cell surface receptors promoting hepatitis B virus infection
-
批准号:10034949
-
项目类别:
-
资助金额:$46.88万
-
财政年份:2020
-
负责人:GUANGXIANG George LUO
-
依托单位:
Role of Human Apolipoprotein E in Hepatitis B Virus Infection and Morphogenesis
-
批准号:10682421
-
项目类别:
-
资助金额:$42.04万
-
财政年份:2020
-
负责人:GUANGXIANG George LUO
-
依托单位:
Cell surface receptors promoting hepatitis B virus infection
-
批准号:10214611
-
项目类别:
-
资助金额:$46.88万
-
财政年份:2020
-
负责人:GUANGXIANG George LUO
-
依托单位:
Cell surface receptors promoting hepatitis B virus infection
-
批准号:10390437
-
项目类别:
-
资助金额:$46.88万
-
财政年份:2020
-
负责人:GUANGXIANG George LUO
-
依托单位:
Underlying Mechanisms of ApoE in HCV Infection and Assembly
-
批准号:8219407
-
项目类别:
-
资助金额:$4.78万
-
财政年份:2012
-
负责人:GUANGXIANG George LUO
-
依托单位:
Underlying Mechanisms of ApoE in HCV Infection and Assembly
-
批准号:8433319
-
项目类别:
-
资助金额:$34.48万
-
财政年份:2012
-
负责人:GUANGXIANG George LUO
-
依托单位:
Underlying Mechanisms of ApoE in HCV Infection and Assembly
-
批准号:9011987
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2012
-
负责人:GUANGXIANG George LUO
-
依托单位:
Underlying Mechanisms of ApoE in HCV Infection and Assembly
-
批准号:8610800
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2012
-
负责人:GUANGXIANG George LUO
-
依托单位:
Underlying Mechanisms of ApoE in HCV Infection and Assembly
-
批准号:8589086
-
项目类别:
-
资助金额:$31.91万
-
财政年份:2012
-
负责人:GUANGXIANG George LUO
-
依托单位:
Viral and Cellular Determinants of HCV Assembly
-
批准号:8589036
-
项目类别:
-
资助金额:$30.75万
-
财政年份:2011
-
负责人:GUANGXIANG George LUO
-
依托单位:
Viral and Cellular Determinants of HCV Assembly
-
批准号:8025067
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2011
-
负责人:GUANGXIANG George LUO
-
依托单位:
Viral and Cellular Determinants of HCV Assembly
-
批准号:8465174
-
项目类别:
-
资助金额:$34.51万
-
财政年份:2011
-
负责人:GUANGXIANG George LUO
-
依托单位:
Viral and Cellular Determinants of HCV Assembly
-
批准号:8282631
-
项目类别:
-
资助金额:$5.95万
-
财政年份:2011
-
负责人:GUANGXIANG George LUO
-
依托单位:
Transgenic mouse models of HCV infection and replication
-
批准号:8031205
-
项目类别:
-
资助金额:$18.56万
-
财政年份:2010
-
负责人:GUANGXIANG George LUO
-
依托单位:
Transgenic mouse models of hepatitis C virus replication
-
批准号:7498472
-
项目类别:
-
资助金额:$17.95万
-
财政年份:2007
-
负责人:GUANGXIANG George LUO
-
依托单位:
Transgenic mouse models of hepatitis C virus replication
-
批准号:7315350
-
项目类别:
-
资助金额:$21.98万
-
财政年份:2007
-
负责人:GUANGXIANG George LUO
-
依托单位:
Hepatitis C virus infection and lipoproteins
-
批准号:7256866
-
项目类别:
-
资助金额:$18.31万
-
财政年份:2007
-
负责人:GUANGXIANG George LUO
-
依托单位:
海外基金